Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Profit After Tax (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Profit After Tax for 4 consecutive years, with -$21.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax rose 71.59% to -$21.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$221.2 million, a 33.82% increase, with the full-year FY2025 number at -$221.2 million, up 33.82% from a year prior.
  • Profit After Tax was -$21.1 million for Q4 2025 at Phathom Pharmaceuticals, up from -$30.0 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$21.1 million in Q4 2025 to a low of -$94.3 million in Q1 2025.
  • A 4-year average of -$59.7 million and a median of -$53.1 million in 2022 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: plummeted 123.23% in 2024, then soared 71.59% in 2025.
  • Phathom Pharmaceuticals' Profit After Tax stood at -$55.0 million in 2022, then tumbled by 44.55% to -$79.6 million in 2023, then rose by 6.43% to -$74.5 million in 2024, then skyrocketed by 71.59% to -$21.1 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Profit After Tax are -$21.1 million (Q4 2025), -$30.0 million (Q3 2025), and -$75.8 million (Q2 2025).